Skip to content

Semnur Pharmaceuticals, Inc.

SMNR SMNRW

CIK 0001913577

← back to feed
Revenue (TTM)
$50M
0.0% YoY Q1 Apr 2026
Net Income (TTM)
−$158.83M
−95,781.8% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$0.80
−3,800.0% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-316.4%
Q1 Apr 2026
Net Margin
-317.7%
Q1 Apr 2026
Free Cash Flow (TTM)
—
Q1 Apr 2026
Cash
$103K
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
230.21M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings